摘要
新型生物制剂的开发为免疫相关性肾病提供了新的治疗策略。抗白细胞分化抗原20单抗、B淋巴细胞刺激因子/增殖诱导配体靶向药物以及补体抑制剂等新型生物制剂通过靶向特定的分子或受体,为免疫介导的肾脏疾病提供更精准的治疗手段,但在治疗有效性、安全性、最佳剂量及在不同肾脏疾病中的适用性等方面尚待进一步研究。该文综述各类新型生物制剂在免疫相关性肾病中的应用进展,旨在探讨其治疗潜力、现有证据及未来研究方向。
The development of novel biologics provides a new therapeutic strategy for immune-related kidney diseases.Novel biologics such as anti-leukocyte differentiation antigen 20 monoclonal antibody,B lymphocyte stimulator/a proliferation-inducing ligand-targeting drugs,and complement inhibitors provide more precise treatment for immunerelated kidney diseases by targeting specific molecules or receptors.However,further studies are needed in terms of therapeutic efficacy,safety,optimal dosage and applicability in different kidney diseases.This article reviewed the application progress of various novel biologics in immune-related kidney diseases,and aimed to discuss their therapeutic potential,existing evidence and future research direction.
作者
张赛男
汪年松
张玮
ZHANG Sainan;WANG Niansong;ZHANG Wei(Department of Nephrology,Yangpu District Hospital of Traditional Chinese Medicine,Shanghai 200090,China;Department of Nephrology,Shanghai Sixth People's Hospital Afiliated to Shanghai Jiao Tong University,Shanghai 200233,China)
出处
《世界临床药物》
2025年第1期1-7,共7页
World Clinical Drug
基金
国家自然基金面上项目(82270761)
国家重点研发计划(2023YFC2411803)
上海市重中之重研究中心建设项目[2022ZZ01002(3)]
上海市进一步加快中医药传承创新发展三年行动计划[ZY(2021-2023)-0205-04]。
关键词
生物制剂
免疫相关性肾病
抗白细胞分化抗原20单抗
B细胞刺激因子/增殖诱导配体靶向药物
补体抑制剂
biological agent
immune-related kidney disease
anti-leukocyte differentiation antigen 20 monoclonal antibody
B lymphocyte stimulator/a proliferation-inducing ligand-targeting drug
complement inhibitor
